GNRH1 and adenomyosis: The administration of GnRH agonist can suppress the hypothalamic–pituitary axis, resulting in a hypoestrogenic status, and then suppress the proliferation of cells derived from the endometrium, reducing the size of pathologic lesions in patients with adenomyosis (27, 28).